Regeneron Entered into a Clinical Supply Agreement with Grey Wolf Therapeutics to Evaluate GRWD5769 + Libtayo (cemiplimab) for Solid Tumour
Shots:
- The companies collaborated to initiate the P-I/II study which evaluates the safety, tolerability, and efficacy of GRWD5769 (ERAP1 inhibitor) + Regeneron’s Libtayo in patients with solid tumors. The study is expected to be initiated in H1’23
- The trial focuses on patients with virally associated solid tumors incl. HNSCC, cervical cancer, and HCC
- GRWD5769 is a potent and selective ERAP1 inhibitor that showed a powerful and differentiated immune response against the tumor. The therapy has the potential to mobilize an entirely new T cell response against tumors and upregulate the generation of novel neoantigens
Ref: Grey Wolf Therapeutics | Image: Regeneron
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
